NCT07497386 2026-03-27
A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Not yet recruiting
Clinical Trials
16 trialsNCT07454668 2026-03-06
Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases
Baptist Health South Florida
Phase 1 Not yet recruiting
NCT07318389 2026-02-27
ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Not yet recruiting
NCT07416253 2026-02-18
Trastuzumab Rezetecan vs Trastuzumab Deruxtecan in the Neoadjuvant Treatment of HER2 Positive Breast Cancer
Henan Cancer Hospital
Phase 2 Not yet recruiting
NCT07368543 2026-01-28
STORM
Fudan University
Phase 2 Not yet recruiting
NCT07340164 2026-01-14
TROY
Yonsei University
Phase 2 Not yet recruiting
NCT07126561 2026-01-08
Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers
University of Chicago
Phase 2 Not yet recruiting
NCT07157956 2025-09-05
CVL006-T1002
Convalife (Shanghai) Co., Ltd.
Phase 1/2 Not yet recruiting
NCT07086768 2025-09-04
Dose-Escalation and Dose-Expansion Study of BSI-082 Monotherapy and Combined Therapy in Patients With Advanced or Metastatic Solid Tumors
The University of Texas Health Science Center at San Antonio
Phase 1 Not yet recruiting
NCT07151586 2025-09-03
ALTER
UNICANCER
Phase 2 Not yet recruiting
NCT07152782 2025-09-03
THUNDER
Fudan University
Phase 2 Not yet recruiting
NCT07150208 2025-09-02
THUMB
Fudan University
Phase 2 Not yet recruiting
NCT07035353 2025-06-25
A Real-world Clinical Study of T-DXd for the Treatment of Chinese Patients With HER2 Overexpressing and HER2 Underexpressing Advanced Breast Cancer
Tianjin Medical University Cancer Institute and Hospital
Not yet recruiting
NCT06797622 2025-01-28
Heterogeneity of 68Ga-FAPI Uptake As Imaging Biomarker in T-DXd Treatment for Brain Metastasis of HER2 Positive Breast Cancer
Fudan University
Phase 2 Not yet recruiting
NCT06245824 2024-02-07
Trastuzumab Deruxtecan (T-DXd) With Pyrotinib in First-line HER2-positive Unresectable or Metastatic Breast Cancer Trial
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 4 Not yet recruiting
NCT05953168 2023-07-19
T-DXd in the First-Line Treatment of Locally Advanced or Metastatic TNBC-LAR HER2-low Patients
Fudan University
Phase 2 Not yet recruiting